Identification of critical microRNAs in gastrointestinal stromal tumor patients treated with Imatinib

• DOI: 10.4149/neo_2018_170906n575
• Publication Date: 2018-08-13T10:49:10Z
• Authors: Z. Zhang; N. y. Jiang; R. y. Guan; Y. k. Zhu; F. q. Jiang; D. Piao
• Keywords: KEGG; Imatinib Mesylate; Stromal tumor

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of gastrointestinal tract.Imatinib mesylate was considered a breakthrough drug in clinical treatment GIST, but GIST patients showed resistance to it.We aimed identify critical microRNAs (miRNAs) related imatinib imatinib-treated patients.Microarray datasets under accession numbers GSE63159 and GSE45901 were downloaded from Gene Expression Omnibus (GEO) database.The differentially expressed miRNAs (DEMs) identified.GO function KEGG pathway enrichment analyses performed, lncRNA-miRNA-target gene regulatory networks constructed.Finally, their target genes or sensitivity identified.A total 20 DEMs dataset (7 significantly up-regulated 13 down-regulated) 23 (8 15 identified.Five 109 identified networks.GO analysis that mainly involved several signaling pathways, such as focal adhesion GnRH pathway.From five miRNAs, overexpression hsa-miR-28-5p hsa-miR-125a-5p had significant correlation patients.In addition, Hsa-miR-28-5p may be development progression they serve prognostic markers for imatinib-response patients.